Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

Artificial intelligence has moved from pilot projects to a central role in many life sciences strategies. What began as a set ...

Executives from Absci (NASDAQ:ABSI) used a conference presentation to emphasize the company’s focus on building ...

About Insilico Medicine: Insilico Medicine is a clinical-stage biotechnology company using AI for drug development across cancer, fibrosis, immunity, central nervous system diseases, and aging-related ...

(Reuters) -U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda Pharmaceutical, deepening their use of artificial intelligence ...

AI accelerates biopharma from discovery to production, cutting cycle times by up to 40%.

One day, probably in the next year or two, a company will claim it has put the first artificial-intelligence-designed antibody in the clinic. But the industry is divided on what “AI-designed” really ...

Explore the new AI foundation model by Insilico Medicine and Liquid AI for efficient pharmaceutical research on private ...

Proteins play a key role not only in the body, but also in medicine: they either serve as active ingredients, such as enzymes or antibodies, or they are target structures for drugs. The first step in ...

Artificial intelligence (AI) is fundamentally reshaping the landscape of solid tumor (ST) drug development. By integrating multi-omics data, spatial transcriptomics, and advanced computational models, ...

A new review titled Artificial Intelligence and the Discovery of Antibiotics: Reinventing with Opportunities, Challenges, and ...